文献速递肿瘤 PET/CT核素与放射性配体治疗

法国ANSM调查:68Ga-PSMA-11 PET/CT在生化复发前列腺癌中的显像方案、检出率与安全性

Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal 18F-fluorocholine PET/CT: 1084 examinations.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-01-08

基于法国6中心1084例近期18F-氟胆碱PET/CT阴性或可疑的生化复发前列腺癌患者,68Ga-PSMA-11 PET/CT总体阳性率为68%,中位血清PSA为1.7 ng/mL时31%呈寡转移模式;阳性率与血清PSA、年龄、初始治疗、FCH结果及既往复发相关,不同显像方案间无显著差异,未报告不良事件。

要点

  • FCH阴性或可疑的生化复发患者中,PSMA-11 PET/CT总体阳性率达68%。
  • 阳性率随血清PSA升高而增加(<0.2 ng/mL为41%,≥2 ng/mL为81%)。
  • 不同显像方案(注射活度、对比剂/呋塞米、采集时间点)阳性率无显著差异。

核心结论

  • 基于FCH PET/CT筛选后,PSMA-11 PET/CT在血清PSA<1 ng/mL时阳性率与独立报道无差异,在≥1 ng/mL时略低。
  • 根据生化临床背景,约四分之一至三分之一的病例观察到寡转移模式,为靶向治疗提供依据。
  • 系统性地采用双/三时间点采集或使用对比剂和/或呋塞米未显著提高PSMA-11 PET/CT阳性率,应个体化决定。

研究设计与样本

  • 法国6个中心在前3年使用期间前瞻性向法国药品管理局(ANSM)提交患者数据以授权, pooled分析1084例PSMA-11 PET/CT。
  • 纳入近期FCH PET/CT结果为阴性或可疑的生化复发前列腺癌患者。

主要发现

  • 总体阳性率为68%,中位血清PSA为1.7 ng/mL时,31%的病例呈寡转移模式(1-3个病灶)。
  • 阳性率与血清PSA显著相关:<0.2 ng/mL为41%,≥2 ng/mL为81%。
  • 阳性率与患者年龄、初始治疗(前列腺切除术后64% vs 未行前列腺切除术85%)、FCH结果(阴性62% vs 可疑82%)及既往生化复发(首次63% vs 既往72%)相关。
  • 注射活度、对比剂和/或呋塞米使用、剂量长度乘积、单次或多时间点图像采集等显像方案间阳性率无显著差异。
  • PSMA-11注射后未报告不良事件,即使联合对比剂和/或呋塞米。

关键数值与推荐

  • 总体阳性率68%(1084例)。
  • 血清PSA<0.2 ng/mL时阳性率41%,≥2 ng/mL时81%。
  • 前列腺切除术后阳性率64%,未行前列腺切除术85%。
  • FCH阴性者阳性率62%,FCH可疑者82%。
  • 首次生化复发阳性率63%,既往生化复发72%。

临床怎么用

  • 对于FCH PET/CT阴性或可疑的生化复发前列腺癌患者,可考虑行68Ga-PSMA-11 PET/CT以定位病灶。
  • 血清PSA水平可帮助预测PSMA-11 PET/CT阳性率,PSA≥2 ng/mL时阳性率较高。
  • 不推荐常规系统性地增加采集时间点或使用对比剂/呋塞米,应根据个体情况决定。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite growing evidence of a superior diagnostic performance of 68Ga-PSMA-11 over 18F-fluorocholine (FCH) PET/CT, the number of PET/CT centres able to label on site with gallium-68 is still currently limited. Therefore, patients with biochemical recurrence (BCR) of prostate cancer frequently undergo FCH as the 1st-line PET/CT. Actually, the positivity rate (PR) of a second-line PSMA-11 PET/CT in case of negative FCH PET/CT has only been reported in few short series, in a total of 185 patients. Our aims were to check (1) whether the excellent PR reported with PSMA-11 is also obtained in BCR patients whose recent FCH PET/CT was negative or equivocal; (2) in which biochemical and clinical context a high PSMA-11 PET/CT PR may be expected in those patients, in particular revealing an oligometastatic pattern; (3) whether among the various imaging protocols for PSMA-11 PET/CT used in France, one yields a significantly highest PR; (4) the tolerance of PSMA-11. PATIENTS AND METHODS: Six centres performed 68Ga-PSMA-11 PET/CTs during the first 3 years of its use in France. Prior to each PET/CT, the patient's data were submitted prospectively for authorisation to ANSM, the French Medicine Agency. The on-site readings of 1084 PSMA-11 PET/CTs in BCR patients whose recent FCH PET/CTs resulted negative or equivocal were pooled and analysed. RESULTS: (1) The overall PR was 68%; for a median serum PSA level (sPSA) of 1.7 ng/mL, an oligometastatic pattern (1-3 foci) was observed in 31% of the cases overall; (2) PR was significantly related to sPSA (from 41% if < 0.2 ng/mL to 81% if ≥ 2 ng/mL), to patients' age, to initial therapy (64% if prostatectomy vs. 85% without prostatectomy due to frequent foci in the prostate fossa), to whether FCH PET/CT was negative or equivocal (PR = 62% vs. 82%), and to previous BCR (PR = 63% for 1st BCR vs. 72% in case of previous BCR); (3) no significant difference in PR was found according to the imaging protocol: injected activity, administration of a contrast agent and/or of furosemide, dose length product, one single or multiple time points of image acquisition; (4) no adverse event was reported after PSMA-11 injection, even associated with a contrast agent and/or furosemide. CONCLUSION: Compared with the performance of PSMA-11 PET/CT in BCR reported independently of FCH PET/CT in 6 large published series (n > 200), the selection based on FCH PET/CT resulted in no difference of PSMA-11 PR for sPSA < 1 ng/mL but in a slightly lower PR for sPSA ≥ 1 ng/mL, probably because FCH performs rather well at this sPSA and very occult BCR was over-represented in our cohort. An oligometastatic pattern paving the way to targeted therapy was observed in one fourth to one third of the cases, according to the clinico-biochemical context of the BCR. Systematic dual or triple acquisition time points or administration of a contrast agent and/or furosemide did not bring a significant added value for PSMA-11 PET/CT positivity and should be decided on individual bases.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Chevalme YM, Boudali L, Gauthé M, et al. Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal 18F-fluorocholine PET/CT: 1084 examinations. Eur J Nucl Med Mol Imaging. 2021. PMID: 33416958. doi:10.1007/s00259-020-05086-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。